StreetInsider.com News Articles

SL Science Holding (SLBT) files for 1.04M share offering by selling stockholders

Fri, 31 Jul 2026 16:05:26 -0400

SL Science Holding (NASDAQ: SLBT) filed for up to 1,040,000 share offering by selling stockholders.

SL Science Holding (SLBT) files for 1.04M share offering by selling stockholders

Fri, 31 Jul 2026 16:05:26 -0400

SL Science Holding (NASDAQ: SLBT) filed for up to 1,040,000 share offering by selling stockholders.

SL Science presents glioblastoma cell therapy data at WCP 2026

Fri, 17 Jul 2026 08:03:21 -0400

SL Science Holding Limited (NASDAQ: SLBT) presented preclinical research on a gamma delta (γδ) T-cell therapy for glioblastoma at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026), held July 12–17 in Melbourne, Australia, according to a company statement.

The research was conducted in collaboration with Taipei Medical University, JY Biomedical Co., Ltd., and HeXun Biosciences Co., Ltd. The study examined the use of expanded γδ T cells administered directly to tumor sites in preclinical models.

Key findings from the preclinical data included complete tumor elimination by day 26 post-treatment at the highest tested dose, which used an 8:1 ratio

SL Science presents glioblastoma cell therapy data at WCP 2026

Fri, 17 Jul 2026 08:03:21 -0400

Key findings from the preclinical data included complete tumor elimination by day 26 post-treatment at the highest tested dose, which used an 8:1 ratio

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Fri, 17 Jul 2026 08:00:00 -0400

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia. Together with its esteemed academic and industry partners, the Company presented highly promising preclinical research

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Fri, 17 Jul 2026 08:00:00 -0400

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

Form 6-K SL Science Holding Ltd For: Jul 10

Fri, 10 Jul 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260710/26755539.html

SL Science files FDA orphan drug request for GDT glioblastoma therapy

Fri, 10 Jul 2026 08:01:13 -0400

SL Science Holding Limited (Nasdaq: SLBT), a Taiwan-based biomedical company, has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration for its Gamma Delta T cell therapy product, Vdelta2+ Gamma Delta T Cells, targeting glioblastoma multiforme (GBM).

The FDA's Office of Orphan Products Development acknowledged receipt of the request, assigned designation request number DRU-2026-11528, and is proceeding with review. The request was received March 30, 2026, and was submitted under Section 526 of the Federal Food, Drug, and Cosmetic Act.

The ODD program applies to therapies targeting diseases affecting fewer than 200,000 patients annually in the United

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Fri, 10 Jul 2026 08:00:00 -0400

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Fri, 10 Jul 2026 08:00:00 -0400

SL Science Holding Limited Reports Full Year 2025 Financial Results

Thu, 18 Jun 2026 17:13:00 -0400

Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025.

Management Commentary

"2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation immunotherapies. Throughout the past year, we strategically prioritized our resources on high-value clinical research and development, committing over $2.07 million to expand

SL Science Holding Limited Reports Full Year 2025 Financial Results

Thu, 18 Jun 2026 17:13:00 -0400

Management Commentary

Form SCHEDULE 13D SL Science Holding Ltd Filed by: Wang Ching-Dong

Thu, 18 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260618/26666748.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Wang Ching-Dong

Thu, 18 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260618/26666742.html

Form 20-F SL Science Holding Ltd For: Jun 12

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666586.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Xu Qian

Wed, 17 Jun 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26658457.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: LAU JOHNSON SHUN-PONG

Tue, 16 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260616/26655289.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Shen Ethan PhD

Tue, 16 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260616/26655269.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Liu Mingche

Tue, 16 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260616/26655260.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Chen Kwo-Liang

Tue, 16 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26655243.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: General John Conrad

Tue, 16 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260616/26655224.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Leung Lok Sang

Tue, 16 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260616/26655190.html

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events.

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among